Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Gogas

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Cancer Discovery|November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaEliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Cancer Research|February 15, 2012
19p13.1 is a triple-negative-specific breast cancer susceptibility locusKristen N Stevens, Zachary Fredericksen, Celine M Vachon, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Cancer Discovery|November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaEliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Cancer Research|February 15, 2012
19p13.1 is a triple-negative-specific breast cancer susceptibility locusKristen N Stevens, Zachary Fredericksen, Celine M Vachon, et al.
Pageof 10